PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients

Table 1 Patient demographics and disease characteristics n (%)

Clinicopathological feature	PIK3CA		P value	TP53		P value	Both PIK3CA and TP53 wild-type	Both PIK3CA and TP53 mutation	Others	P value
	Wild-type	Mutation		Wild-type	Mutation
Age (yr)
< 60	52 (26.80)	29 (23.97)		31 (28.18)	50 (24.39)		26 (31.33)	22 (28.57)	33 (21.29)
60-70	47 (24.23)	33 (27.27)		28 (25.45)	52 (25.37)		20 (24.10)	18 (23.38)	42 (27.10)
≥ 70	95 (48.97)	59 (48.76)	0.776	51 (46.36)	103 (50.24)	0.733	37 (44.58)	37 (48.05)	80 (51.61)	0.500
Sex
Male	107 (55.15)	73 (60.33)		67 (60.91)	113 (55.12)		47 (56.63)	45 (58.44)	88 (56.77)
Female	87 (44.85)	48 (39.67)	0.367	43 (39.09)	92 (44.88)	0.322	36 (43.37)	32 (41.56)	67 (43.23)	0.965
Tumor location
Rectum	109 (56.19)	53 (43.80)		53 (48.18)	109 (53.17)		48 (57.83)	41 (53.25)	73 (47.10)
Proximal	39 (20.10)	39 (32.23)		32 (29.09)	46 (22.44)		17 (20.48)	19 (24.68)	42 (27.10)
Distal	46 (23.71)	29 (23.97)	0.036	25 (22.73)	50 (24.39)	0.426	18 (21.69)	17 (22.08)	40 (25.81)	0.601
Stage T
T1-T2	34 (17.53)	26 (21.49)		20 (18.18)	40 (19.51)		15 (18.07)	16 (20.78)	29 (18.71)
T3	38 (19.59)	19 (15.70)		21 (19.09)	36 (17.56)		17 (20.48)	11 (14.29)	29 (18.71)
T4	122 (62.89)	76 (62.81)	0.539	69 (62.73)	129 (62.93)	0.923	51 (61.45)	50 (64.94)	97 (62.58)	0.884
Stage N
N0	118 (60.82)	70 (57.85)		68 (61.82)	120 (58.54)		53 (63.86)	45 (58.44)	90 (58.06)
N1	55 (28.35)	35 (28.93)		28 (25.45)	62 (30.24)		20 (24.10)	23 (29.87)	47 (30.32)
N2	21 (10.82)	16 (13.22)	0.785	14 (12.73)	23 (11.22)	0.656	10 (12.05)	9 (11.69)	18 (11.61)	0.889
Stage
I	23 (11.86)	23 (19.01)		16 (14.55)	30 (14.63)		12 (14.46)	14 (18.18)	20 (12.90)
II	86 (44.33)	42 (34.71)		47 (42.73)	81 (39.51)		37 (44.58)	28 (36.36)	63 (40.65)
III	70 (36.08)	43 (35.54)		38 (34.55)	75 (36.59)		27 (32.53)	26 (33.77)	60 (38.71)
IV	15 (7.73)	13 (10.74)	0.166	9 (8.18)	19 (9.27)	0.948	7 (8.43)	9 (11.69)	12 (7.74)	0.774